We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
Read MoreHide Full Article
Key Takeaways
GSK's Arexvy may be approved in Europe for adults 18 following EMA's acceptance of its application.
The RSV vaccine is currently cleared for adults 60 and high-risk individuals aged 50-59 years.
Arexvy sales fell 57% in the first quarter of 2025 due to lower demand in the United States.
GSK plc (GSK - Free Report) announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, for use in adults aged 18 years and above.
With the EMA accepting the application for review, a final decision from the regulatory body in Europe is expected in the first half of 2026.
Arexvy is currently approved for the prevention of lower respiratory tract disease (“LRTD”) caused by RSV in all individuals aged 60 years and above, as well as for high-risk individuals aged 50-59 years.
GSK is currently seeking approval for the expanded use of Arexvy in adults aged 18 years and above in the United States and Japan.
Year to date, shares of GSK have risen 20.8% against the industry’s decline of 0.6%.
Image Source: Zacks Investment Research
GSK's Arexvy Sales Remain Lukewarm
Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world.
However, sales of the vaccine have been lukewarm, mainly due to the revised recommendations for RSV vaccinations issued by the Advisory Committee on Immunization Practices (“ACIP”) in June 2024.
In June, the ACIP recommended the use of Arexvy for all adults aged 75 years and above. However, for adults aged 60-74 years, the ACIP recommended the vaccine only for those who are at increased risk of severe RSV disease.
Arexvy generated sales worth £78 million in the first quarter of 2025, down 57% year over year due to lower demand in the United States.
Other RSV Vaccine Makers in the Market
Pfizer’s (PFE - Free Report) Abrysvo is approved for the prevention of RSV-associated LRTD in all individuals aged 60 years and above, as well as in infants, through maternal immunization.
PFE’s Abrysvo is also approved for use in high-risk adults aged 18-59 years in the United States and Europe.
Earlier this year, the ACIP recommended the expanded use of Arexvy and Abrysvo for use in adults aged 50-59 years who are at high risk for severe RSV disease. The updated ACIP recommendation lowers the recommended age for RSV vaccination from 60 years to 50 years for high-risk adults.
The ACIP’s recommendation is pending final approval by the director of the U.S. Centers for Disease Control and Prevention (“CDC”) and the Department of Health and Human Services.
Moderna’s (MRNA - Free Report) RSV vaccine, mResvia, was approved last year by the FDA and the European Commission to prevent RSV-LRTD in older adults aged 60 years and above.
Last week, the FDA approved MRNA’s mResvia for use in high-risk adults aged 18-59 years. Moderna is also working on expanding the vaccine’s use in pediatric populations.
We note that RSV vaccine sales have been weak across the industry for the 2024-2025 vaccination season due to the restrictive recommendation issued by the U.S. CDC last year for individuals in the 60-74 age bracket.
mResvia generated sales worth $2 million during the first quarter of 2025, while sales of Pfizer’s RSV vaccine, Abrysvo, fell 9% year over year to $131 million.
Image: Bigstock
EMA Accepts GSK's Filing for Expanded Use of RSV Vaccine Arexvy
Key Takeaways
GSK plc (GSK - Free Report) announced that the European Medicines Agency (EMA) has accepted the regulatory application seeking approval to expand the use of its adjuvanted recombinant respiratory syncytial virus (RSV) vaccine, Arexvy, for use in adults aged 18 years and above.
With the EMA accepting the application for review, a final decision from the regulatory body in Europe is expected in the first half of 2026.
Arexvy is currently approved for the prevention of lower respiratory tract disease (“LRTD”) caused by RSV in all individuals aged 60 years and above, as well as for high-risk individuals aged 50-59 years.
GSK is currently seeking approval for the expanded use of Arexvy in adults aged 18 years and above in the United States and Japan.
Year to date, shares of GSK have risen 20.8% against the industry’s decline of 0.6%.
Image Source: Zacks Investment Research
GSK's Arexvy Sales Remain Lukewarm
Arexvy was the first RSV vaccine for older adults to be approved anywhere in the world.
However, sales of the vaccine have been lukewarm, mainly due to the revised recommendations for RSV vaccinations issued by the Advisory Committee on Immunization Practices (“ACIP”) in June 2024.
In June, the ACIP recommended the use of Arexvy for all adults aged 75 years and above. However, for adults aged 60-74 years, the ACIP recommended the vaccine only for those who are at increased risk of severe RSV disease.
Arexvy generated sales worth £78 million in the first quarter of 2025, down 57% year over year due to lower demand in the United States.
Other RSV Vaccine Makers in the Market
Pfizer’s (PFE - Free Report) Abrysvo is approved for the prevention of RSV-associated LRTD in all individuals aged 60 years and above, as well as in infants, through maternal immunization.
PFE’s Abrysvo is also approved for use in high-risk adults aged 18-59 years in the United States and Europe.
Earlier this year, the ACIP recommended the expanded use of Arexvy and Abrysvo for use in adults aged 50-59 years who are at high risk for severe RSV disease. The updated ACIP recommendation lowers the recommended age for RSV vaccination from 60 years to 50 years for high-risk adults.
The ACIP’s recommendation is pending final approval by the director of the U.S. Centers for Disease Control and Prevention (“CDC”) and the Department of Health and Human Services.
Moderna’s (MRNA - Free Report) RSV vaccine, mResvia, was approved last year by the FDA and the European Commission to prevent RSV-LRTD in older adults aged 60 years and above.
Last week, the FDA approved MRNA’s mResvia for use in high-risk adults aged 18-59 years. Moderna is also working on expanding the vaccine’s use in pediatric populations.
We note that RSV vaccine sales have been weak across the industry for the 2024-2025 vaccination season due to the restrictive recommendation issued by the U.S. CDC last year for individuals in the 60-74 age bracket.
mResvia generated sales worth $2 million during the first quarter of 2025, while sales of Pfizer’s RSV vaccine, Abrysvo, fell 9% year over year to $131 million.
GSK's Zacks Rank
GSK currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.